CommodityCoverage
4 minutes ago
Allowing the company to proceed with its multi-center trial in France and the Netherlands, evaluating the safety, tolerability, and efficacy of TTI-0102 in 12 patients over six months, Thiogenesis Therapeutics (TTI.v) has received final regulatory clearance from the European Medicines Agency (EMA) t